Relay Therapeutics Inc Total Assets
Relay Therapeutics Inc total assets. Based on the latest financial reports, Relay Therapeutics Inc (RLAY) holds total assets worth $699.61 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Relay Therapeutics Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Total Assets of Relay Therapeutics Inc (2018–2025)
Total assets of Relay Therapeutics Inc from 2018 to 2025. This chart illustrates how Relay Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Relay Therapeutics Inc share price for real-time trading data and today's change.
Relay Therapeutics Inc - Asset Composition Analysis
Relay Therapeutics Inc Total Assets Breakdown (December 2025)
Relay Therapeutics Inc total assets breakdown as of December 2025. Relay Therapeutics Inc's total assets of $699.61 Million consist of 93.1% current assets and 6.9% non-current assets. Explore how liquid is Relay Therapeutics Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Relay Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Relay Therapeutics Inc's current assets represent 93.1% of total assets in 2025, a decrease from 99.0% in 2018.
- Cash Position: Cash and equivalents constituted 13.5% of total assets in 2025, down from 98.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Relay Therapeutics Inc Competitors by Total Assets
Key competitors of Relay Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.98 Billion |
Relay Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 22.13 | 19.96 | 26.84 |
| Quick Ratio | 22.13 | 19.96 | 26.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $628.71 Million | $702.61 Million | $655.89 Million |
Relay Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Relay Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.93 |
| Latest Market Cap to Assets Ratio | 4.74 |
| Asset Growth Rate (YoY) | -28.7% |
| Total Assets | $621.33 Million |
| Market Capitalization | $2.95 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Relay Therapeutics Inc's assets at a significant premium (4.74x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Relay Therapeutics Inc's assets decreased by 28.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Relay Therapeutics Inc (2018–2025)
The table below shows the annual total assets of Relay Therapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $621.33 Million | -28.69% |
| 2024-12-31 | $871.30 Million | +3.24% |
| 2023-12-31 | $843.98 Million | -23.26% |
| 2022-12-31 | $1.10 Billion | +9.06% |
| 2021-12-31 | $1.01 Billion | +26.08% |
| 2020-12-31 | $799.83 Million | +103.48% |
| 2019-12-31 | $393.07 Million | -8.29% |
| 2018-12-31 | $428.61 Million | -- |
About Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Ka, inhibitor that is in clin… Read more